Trial 3P-23-1


A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine with or without Botensilimab (AGEN1811) in Patients with Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: USC Koreatown, USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Diana Hanna, M.D.
Other Trial Staff:  Charlean Ketchens, R.N., Jiayi Jiang, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Angela Smith Bryant, Coordinator, Young-Wook Kim, Coordinator, Syed Husein, D.M., Diane Chun, Coordinator, Liza Pizarro, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.